Home › Trials › NCT05478213
Clinical trial Recruiting at 3 sites Interventional Ages 18 and up

Understanding the causes of ventricular tachycardia

Official title: Ventricular Tachycardia Substrate Mechanisms Revealed by Local Repolarization and Conduction Parameters

Run by Emory University · NCT05478213 · Data updated 2026-11-12

This study is trying to find out what causes ventricular tachycardia by looking at heart tissue during treatment to help improve the success of the procedure for patients.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment10 (estimated)
SponsorEmory University
Academic / other
Locations3 sites (Atlanta, Georgia and 2 other locations)
StatusRecruiting
StartedOctober 25, 2022
Main results expectedMay 2027
Study endsMay 2027
Registry record updatedJune 30, 2026
Trial IDNCT05478213 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are patients diagnosed with ischemic cardiomyopathy who have a single or dual chamber implantable cardioverter-defibrillator.

Probably not a fit

Patients with non-ischemic cardiomyopathy or those who have contraindications to catheter ablation may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to investigate the mechanisms behind ventricular tachycardia (VT) by examining the electrical properties of heart tissue. Researchers will utilize a Monophasic Action Potential (MAP) catheter during standard VT ablation procedures to identify critical areas of the myocardium that may lead to arrhythmias. The goal is to improve the success rates of VT ablation, which currently have a high recurrence rate despite advancements in technology. By better understanding the cellular action potentials, the study hopes to enhance patient outcomes during VT treatment.

Why it matters

Potential benefit: If successful, this study could lead to improved outcomes for patients undergoing ventricular tachycardia ablation.

How similar studies have gone: Previous studies have shown modest improvements in VT ablation success rates using various mapping techniques, but this approach utilizing MAP signals is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Diagnosis of ischemic cardiomyopathy
* Single or dual chamber implantable cardioverter-defibrillator (ICD)

Exclusion Criteria:

* Non-Ischemic cardiomyopathy
* Contraindication to catheter ablation
* Severe peripheral arterial disease or medical condition that prohibit arterial access
* Ventricular tachycardia (VT) or sudden cardiac arrest (SCA) within 30 days of acute coronary syndrome or within 90 days of coronary revascularization

Where it's running

  • Emory University Hospital Midtown
    Atlanta, Georgia, United States     Recruiting
  • Emory Clinic
    Atlanta, Georgia, United States     Recruiting
  • Emory University Hospital
    Atlanta, Georgia, United States     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Ventricular Tachycardia 59Emory University 2068
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.